EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Leflunomide Applicability in Rheumatoid Arthritis: Drug Delivery Challenges and Emerging Formulation Strategies

Ashish Dhiman, Kalpna Garkhal

Drugs and Drug Candidates · 01.08.2025 · 4 (3) · 36

DOI: 10.3390/ddc4030036 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drugs and Drug Candidates, online erschienen am 01.08.2025. Verfasst von Ashish Dhiman und 1 weiteren Autor:innen. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rheumatoid arthritis (RA) is a chronic systemic inflammatory disorder primarily targeting joints, leading to pain, swelling, and stiffness. RA results from the body’s own immune system attacking its own tissues. Currently, there are various treatments available for RA including disease-modifying antirheumatic drugs (DMARDs) and NSAIDs. Leflunomide (LEF) is a USFDA-approved synthetic DMARD which is being widely prescribed for the management of RA; however, it faces several challenges such as prolonged drug elimination, hepatotoxicity, and others. LEF exerts its therapeutic effects by inhibiting dihydroorotate dehydrogenase (DHODH), thereby suppressing pyrimidine synthesis and modulating immune responses. Emerging nanotechnology-based therapies help in encountering the current challenges faced in LEF delivery to RA patients. This review enlists the LEF’s pharmacokinetics, mechanism of action, and clinical efficacy in RA management. A comparative analysis with methotrexate, biologics, and other targeted therapies, highlighting its role in monotherapy and combination regimens and the safety concerns, including hepatotoxicity, gastrointestinal effects, and teratogenicity, is discussed alongside recommended monitoring strategies. Additionally, emerging trends in novel formulations and drug delivery approaches are explored to enhance efficacy and minimize adverse effects. Overall, LEF remains a perfect remedy for RA patients, specifically individuals contraindicated with drugs like methotrexate. The therapeutic applicability of LEF could be enhanced by developing more customized treatments and advanced drug delivery approaches.

Zitieren

APA

Dhiman, A., & Garkhal, K. (2025). Leflunomide Applicability in Rheumatoid Arthritis: Drug Delivery Challenges and Emerging Formulation Strategies. Drugs and Drug Candidates, 4(3), 36. https://doi.org/10.3390/ddc4030036

Vancouver

Dhiman A, Garkhal K. Leflunomide Applicability in Rheumatoid Arthritis: Drug Delivery Challenges and Emerging Formulation Strategies. Drugs and Drug Candidates. 2025;4(3):36. doi:10.3390/ddc4030036

BibTeX
@article{Dhiman2025,
  author = {Dhiman, Ashish and Garkhal, Kalpna},
  title = {Leflunomide Applicability in Rheumatoid Arthritis: Drug Delivery Challenges and Emerging Formulation Strategies},
  journal = {Drugs and Drug Candidates},
  year = {2025},
  volume = {4},
  number = {3},
  pages = {36},
  doi = {10.3390/ddc4030036}
}
Kostenlos starten →